SCHEMBL1924673

SCHEMBL1924673

Cc1cc(-c2cc(C(F)(F)F)n3cnc(-c4ccncc4)c3n2)ccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.36
GRM2 Q14416 2/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
FLT1 P17948 1/20 0.34
KDR P35968 1/20 0.34
MAPK14 Q16539 3/20 0.34
MAPT P10636 3/20 0.34
MAPK13 O15264 2/20 0.33
MAPK12 P53778 2/20 0.33
MAPK11 Q15759 2/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926709 0.91 S1PR1 (0.46) S1PR1KDM4EALDH1A1HPGDTSHR
SCHEMBL1924539 0.90 NOTUM (0.36) S1PR1KDM4EALDH1A1HPGDTSHR
SCHEMBL1925912 0.89 GRM2 (0.46) S1PR1GRM2
SCHEMBL1924385 0.88 TP53 (0.35) S1PR1GRM2KDM4EALDH1A1HPGD
SCHEMBL1926435 0.88 CYP11B2 (0.42) GRM2KDM4EALDH1A1MAPK14MAPK13
SCHEMBL1925499 0.88 TP53 (0.43) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL1925301 0.85 CTSS (0.41) S1PR1GRM2KDM4EALDH1A1HPGD
SCHEMBL1923886 0.84 CTSS (0.37) GRM2KDM4EALDH1A1HPGDTSHR
SCHEMBL1924870 0.84 KIF11 (0.44) KDM4EALDH1A1HPGDKDRMAPK14
SCHEMBL1924970 0.83 CTSS (0.47) CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7514443-B2 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors HOFFMANN-LA ROCHE INC. (US) 2009-04-07 US disclosed
US-20080051421-A1 Pyrazolo-pyridine WICHMANN JUERGEN 2008-02-28 US disclosed
US-7329662-B2 Pyrazolo-pyridine HOFFMANN-LA ROCHE INC. (US) 2008-02-12 US disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR S1PR1 967/4885GRM2 219/4885KDM4E 1251/4885
US-20080051421-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR S1PR1 967/4885GRM2 219/4885KDM4E 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.